Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. by Pietrogrande, M et al.
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is
posted here by agreement between Elsevier and the University of Turin. Changes resulting
from the publishing process - such as editing, corrections, structural formatting, and other
quality control mechanisms - may not be reflected in this version of the text. The definitive
version of the text was subsequently published in AUTOIMMUNITY REVIEWS, 10,
2011, 10.1016/j.autrev.2011.01.008.
You may download, copy and otherwise use the AAM for non-commercial purposes
provided that your license is limited by the following restrictions:
(1) You may use this AAM for non-commercial purposes only under the terms of the
CC-BY-NC-ND license.
(2) The integrity of the work and identification of the author, copyright owner, and
publisher must be preserved in any copy.
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en),
10.1016/j.autrev.2011.01.008
The definitive version is available at:
http://www.sciencedirect.com/science/article/pii/S1568997211000231
Recommendations for the management of mixed 
cryoglobulinemia syndrome in hepatitis C virus-infected patients 
Maurizio Pietrograndea, 1,Salvatore De Vitab, 1, Anna Linda Zignegoc, 1, Pietro Pioltellid, 1, Domenico 
Sansonnoe, 1, Salvatore Sollimaf, 1, Fabiola Atzenig, 1, Francesco Saccardoh, 1,Luca Quartucciob, 1,Savino 
Brunoi, 1, Raffaele Brunoj, 1, Mauro Campaninik, 1, Marco Candelal, 1, Laura Castelnovoh, 1,Armando 
Gabriellim, 1, Giovan Battista Gaetan, 1, Piero Marsono, 1, Maria Teresa Masciap, 1, Cesare Mazzaroq, 1, Francesco 
Mazzotta
r, 1
, Pierluigi Meroni
s, 1
, Carlomaurizio Montecucco
t, 1
, Elena Ossi
u, 1
,Felice 
Piccinino
v, 1
, Daniele Prati
w, 1
, Massimo Puoti
x, 1
, Piersandro Riboldi
y, 1
, Agostino Riva
f, 1
, Dario 
Roccatello
z, 1
, Evangelista Sagnelli
v, 1
, Patrizia Scaini
aa, 1
, Salvatore Scarpato
ab, 1
, Renato 
Sinico
ac, 1
,Gloria Taliani
ad, 1
, Antonio Tavoni
ae, 1
, Eleonora Bonacci
a
, Piero Renoldi
ac, 1
, Davide 
Filippini
af, 1
,Piercarlo Sarzi-Puttini
g, 1
, Clodoveo Ferri
ag, 1
, Giuseppe Monti
h, 1
, Massimo Galli
f, 
 
a
 Medicina Interna, Department of Medicine, Surgery and Dentistry, Policlinico San Marco of Zingonia, 
University of Milan, Italy 
b
 Rheumatology Clinic, DPMSC, University of Udine, Italy 
c
 Medicina Interna, University of Florence, Italy 
d
 Clinica Ematologica, AO San Gerardo, University of Milan — Bicocca, Italy 
e
 Medicina Interna, DIMO, University of Bari, Italy 
f
 Infectious Disease Unit, L. Sacco Department of Clinical Sciences, University of Milan, Italy 
g
 Rheumatology Unit, Ospedale L. Sacco, Milan, Italy 
h
 Medicina Interna, Ospedale di Saronno, AO Busto Arsizio, Italy 
i
 Dipartimento di Medicina Interna, AO Fatebenefratelli e Oftalmico, Milan, Italy 
j
 U.O. Malattie Infettive e Tropicali, Fondazione IRCCS Policlinico S Matteo, University of Pavia, Italy 
k
 Divisione di Medicina Generale, Ospedale Maggiore di Novara, AO Maggiore della Carità, Novara, 
Italy 
l
 ASUR Marche ZT6, Fabriano, Italy 
m
 Clinica Medica Generale, Ematologia ed Immunologia Clinica, University of Ancona, Italy 
n
 Unità di Epatologia, Seconda Università di Napoli, Naples, Italy 
o
 Unità Immunotrasfusionale, AO di Padova, Italy 
p
 Unità di Malattie dell'apparato locomotore a genesi immunologica — Policlinico, University of 
Modena, Italy 
q
 Medicina Generale, AO Santa Maria degli Angeli, Pordenone, Italy 
r
 Infectious Diseases Unit, Azienda Sanitaria Firenze, Florence, Italy 
s
 Clinica Reumatologica, University of Milan, Italy 
t
 Clinica Reumatologica, Fondazione IRCCS Policlinico S Matteo, University of Pavia, Italy 
u
 Clinica Medica 1, University of Padua, Italy 
v
 Dipartimento di Medicina Pubblica, Sezione Malattie Infettive, Seconda Università di Napoli, Naples, 
Italy 
w
 Department of Transfusion Medicine and Hematology, Ospedale Alessandro Manzoni, Lecco; and 
Laboratory of Experimental Hepatology, Centre of Transfusion Medicine, Cellular Therapy and 
Cryobiology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 
x
 Department of Infectious Diseases, University of Brescia, Italy 
y
 Allergy, Clinical Immunology and Rheumatology Unit, Istituto Auxologico Italiano, Department. of 
Internal Medicine, University of Milan, Italy 
z
 Divisione di Nefrologia e Dialisi, Ospedale Giovanni Bosco, Turin, Italy 
aa
 UO Nefrologia, Spedali Civili, Brescia, Italy 
ab
 UO Reumatologia, Ospedale M. Scarlato, Scafati, Salerno, Italy 
ac
 UOS di Immunologia Clinica, Ospedale S. Carlo Borromeo, Milan, Italy 
ad
 Dipartimento di Malattie Infettive e Tropicali, Policlinico di Roma, La Sapienza University, Rome, 
Italy 
ae
 Dipartimento di Medicina Interna, Unità di Reumatologia, University of Pisa, Italy 
af
 Unità di Reumatologia, Ospedale Niguarda Ca’ Granda, Milan, Italy 
ag
 Rheumatology Unit, Department of Internal Medicine, University of Modena and Reggio Emilia, Italy 
 
 
Keywords: Cryoglobulinemia Mixed cryoglobulinemia syndrome HCV Pegylated interferon Ribavirin 
Rituximab Glucocorticoids Apheresis Cyclophosphamid 
 
Abstract 
Objective: The objective of this review was to define a core set of recommendations for the treatment of 
HCVassociated mixed cryoglobulinemia syndrome (MCS) by combining current evidence from clinical trials 
and expert opinion. Methods: Expert physicians involved in studying and treating patients with MCS 
formulated statements after discussing the published data. Their attitudes to treatment approaches 
(particularly those insufficiently supported by published data) were collected before the consensus 
conference by means of a questionnaire, and were considered when formulating the statements. Results: An 
attempt at viral eradication using pegylated interferon plus ribavirin should be considered the first-line 
therapeutic option in patients with mild–moderate HCV-related MCS. Prolonged treatment (up to 72 weeks) 
may be considered in the case of virological non-responders showing clinical and laboratory improvements. 
Rituximab (RTX) should be considered in patients with severe vasculitis and/or skin ulcers, peripheral 
neuropathy or glomerulonephritis. High-dose pulsed glucocorticoid (GC) therapy is useful in severe 
conditions and, when necessary, can be considered in combination with RTX; on the contrary, the majority 
of conference participants discouraged the chronic use of low–medium GC doses. Apheresis remains the 
elective treatment for severe, life-threatening hyper-viscosity syndrome; its use should be limited to patients 
who do not respond to (or who are ineligible for) other treatments, and emergency situations. 
Cyclophosphamide can be considered in combination with apheresis, but the data supporting its use are 
scarce. Despite the limited available data, colchicine is used by many of the conference participants, 
particularly in patients with mild–moderate MCS refractory to other therapies. Careful monitoring of the side 
effects of each drug, and its effects on HCV replication and liver function tests is essential. A low-
antigencontent diet can be considered as supportive treatment in all symptomatic MCS patients. Although 
there are no data from controlled trials, controlling pain should always be attempted by tailoring the 
treatment to individual patients on the basis of the guidelines used in other vasculitides. Conclusion: 
Although there are few controlled randomised trials of MCS treatment, increasing knowledge of its 
pathogenesis is opening up new frontiers. The recommendations provided may be useful as provisional 
guidelines for the management of MCS. 
 
Introduction  
Mixed cryoglobulins (MCs) are immune complexes that typically consist of an IgM rheumatoid factor and 
immunoglobulins (most frequently IgG) that can precipitate at temperatures below 37 °C [1]. Associated 
with acute and chronic infections, lymphoproliferative disorders, and autoimmune diseases, they often have 
no real pathological significance but, in some cases, they may be responsible for serious and debilitating 
vasculitis syndromes with organ damage and a sometimes fatal outcome [2]. The mixed cryoglobulinemia 
syndrome (MCS) or symptomatic mixed cryoglobulinemia is defined by the Meltzer and Franklin triad of 
purpura, fatigue and arthralgia [3], and can be classified as one of the immune complex-mediated systemic 
vasculitides involving small-sized vessels. Since the discovery of hepatitis C virus (HCV), it has been shown 
that the vast majority of MCs previously defined as ‘essential’ or idiopathic can be attributed to it [4–7]. 
Circulating cryoglobulins are frequently detected in HCV-positive patients, but only a minority of patients 
with chronic HCV infections (usually women aged more than 50 years) develop frank MCS [8]. However, 
although it is generally considered to be rare, MCS is actually not uncommon, especially in southern 
European countries where the prevalence of HCV infection is high among the elderly. Various attempts at 
defining a clinical classification have been made since the 1990s and the GISC (Italian Group for the Study 
of Cryoglobulinemia) has recently completed a large international cooperative study aimed at establishing 
classification criteria on the basis of standard methods [9]. Managing MCS means dealing with multiple and 
often very different clinical patterns, activity and severity, and should have the aim of preventing irreversible 
organ damage, reducing pain and improving the patients' quality of life. However, the treatment is still 
largely empirical. Any rational therapeutic approach should have three main objectives [10]: to eradicate 
HCV; to limit or suppress B lymphocyte proliferation; and to contain and symptomatically treat the vasculitis 
and reduce the damage caused by circulating immune complexes. Each of these therapeutic targets requires 
the use of different classes of drugs or specific procedures, but there are still very few data available from 
randomised controlled studies. Furthermore, the involvement of different organs means that MCS may be 
diagnosed by specialists in different fields, who tend to focus on the therapeutic approaches that are more in 
line with their own experience. For this reason, the GISC promoted a consensus conference to discuss 
currently used therapies and the published evidence concerning their efficacy. The aim of this conference 
was to define a core set of practical treatment recommendations by combining clinical trial data and expert 
opinion. 
 
Methods  
For practical reasons, the GISC board organising the conference focused on what is known about the drugs 
used to treat MCS. The discussion was also strictly limited to the treatment of HCV-related MCS. The 
Consensus Committee included physicians working in various medical fields (internal medicine, 
rheumatology, haematology, nephrology, hepatology, infectious diseases, and neurology) who were involved 
in caring for patients with MCS. The therapeutic schedules currently used by each GISC centre were 
collected by means of a questionnaire and submitted for preliminary evaluation by the GISC Scientific 
Board. The questionnaire asked which of the following drugs or treatment procedures were used to treat 
MCS: interferons ± ribavirin; pegylated interferons± ribavirin; anti-CD20; glucocorticoids; 
immunosuppressors, including cyclophosphamide, azatioprine, methotrexate, and cyclosporine; colchicine; 
NSAIDs and other drugs used in pain control; apheretic procedures; and a lowantigen-content diet. These 
were then divided into three groups to be discussed at the conference: 1) antiviral (interferon-based) 
therapies; 2) biological (anti-CD20-based) therapies; and 3) other therapeutic approaches. A panel of four 
members (two senior clinicians plus two junior clinicians as bibliographic reviewers) was formed for each 
group and, after carefully reviewing the literature and questionnaires (see below), each panel formulated 
preliminary statements to be discussed at the consensus conference by the full Consensus Committee. The 
literature review was carried out in phases based on the Cochrane systematic review guidelines [11]. The 
results of the review and the experts' discussions were then translated into epidemiological terms using 
Sackett's patients, intervention, comparison and outcome (PICO) methods [12]. Specific key words and 
MeSh terms were selected in MEDLINE and variously combined to search for papers concerning the 
treatment of patients aged more than 18 years with HCV-related MCS available in MEDLINE, EMBASE 
and Cochrane Central. The search was restricted to papers written in English, French and Italian. The 
selected papers included randomised controlled trials (RCTs), observational studies (prospective and 
retrospective cohort and case– control studies), and case series of at least three patients. Given the scarcity of 
data concerning some treatments, the Scientific Committee also included single case reports that provided 
information about otherwise neglected issues. The publication details, patient characteristics, dosage, 
therapeutic strategy and relevant outcomes were extracted from all of the included articles using standard 
forms. Levels of evidence (Oxford, May 2001, http://www.cebm.net) of each study were assessed and 
classified from level 1a (a systematic review of RCTs) to level 4 (case series), with level 5 being used for 
expert opinions without any explicit critical appraisal. The strength of the experts' recommendations was 
classified from A (consistent level 1 studies) to D (inconsistent or inconclusive studies at any level). The 
statements formulated on these bases were then discussed by the panel of experts together, and the 
recommendations were reformulated by combining the best available evidence from the literature with the 
experts' opinion. A second level of agreement was provided for each recommendation by the committee 
members who had acknowledged competence in the field of each recommendation. Subsequently published 
additional data were taken into account when preparing the final report, which was resubmitted to the expert 
panel for a final on-line discussion. 
 
Results 
Antiviral therapy  
Since the discovery of the association between HCV and MCS, many studies have assessed the efficacy of 
antiviral therapy [13]. Interestingly, because of its antiproliferative and immunomodulatory effects, 
interferon-α (IFN) was successfully used to treat MC even before the identification of HCV [14,15]. The 
antiviral treatment of MCS essentially followed the evolution of chronic hepatitis C treatment, but the studies 
are difficult to compare because of the heterogeneity of treatment regimens, patient selection, response 
evaluations, and follow-up [16]. Furthermore, they all had poor statistical power because of their small 
sample sizes. The first studies of the effects of IFN monotherapy showed the remission of symptoms in the 
majority of patients, but this benefit was often transient and relapses were very frequent after treatment 
discontinuation [17–34]. However, the presence of cryoglobulinemia did not affect the response to IFN in 
patients with chronic HCV infection [34–36]. It is also worth noting that the regression of peripheral blood 
and bone marrow monoclonal B lymphocytes was observed in the MCS patients who cleared HCV as a 
result of IFN therapy [37]. In comparison with IFN monotherapy, IFN plus ribavirin (RBV) improved viral 
eradication and the cure of symptoms [38–44]. However, only the patients who cleared the virus achieved a 
complete and sustained clinical response [38,39,41–43]. Once again, the presence of cryoglobulins did not 
affect the response to antiviral treatment [39] and it was confirmed that antiviral therapy can induce the 
disappearance of circulating B cell clones bearing the t(14;18) translocation [45–47]. Over the last ten years, 
the development of pegylated IFN (Peg-IFN) α-2a and α-2b, which have prolonged bioavailability and 
greater antiviral efficacy than standard IFN, has opened up new opportunities for the treatment of HCV-
related chronic hepatitis and MCS [48–50]. Peg-IFN combined with ribavirin is now the standard of care for 
HCV treatment and leads to 41–54% sustained viral responses (SVRs) in the case of genotype 1, and 
approximately 80% in the case of genotypes 2 and 3. SVR is defined as undetectable HCV viremia six 
months after the completion of antiviral therapy [51]. There are only two pilot studies of the treatment of 
MCS with PegIFN+RBV [52,53], although additional data can be gathered from a few other studies in which 
both standard IFN and Peg-IFN were used [54,55]. Mazzaro et al. [52] studied 18 consecutive MCS patients 
treated with Peg-IFN α-2b (1 μg/kg/week) and RBV (1000 mg/day) for 48 weeks, after which 15 patients 
(83%) had undetectable HCV RNA levels, and most of the patients showed a clinical improvement. At the 
end of the 6- month follow-up period, only eight patients (44%) were sustained clinical and virological 
responders, and cryoglobulins had disappeared in six cases (33%). One major weakness of this study was the 
use of a Peg-IFN dose that was lower than that usually recommended in HCV therapeutic guidelines. Cacoub 
et al. [53] studied nine consecutive MCS patients (78% with HCV genotype 1) who received Peg-IFN α-2b 
(1.5 μg/kg/week) and RBV (800–1200 mg/day) for a mean of 13.5 months (range of 10–26). After a mean 
follow-up of 18.6 months (range of 6–33) following the discontinuation of antiviral therapy, seven patients 
(78%) showed a SVR and were complete clinical responders, and one a partial virological and a complete 
clinical response. The treatment was found to be safe and well tolerated in both of these studies, which 
demonstrated that in HCV-associated MCS combined Peg-IFN+RBV therapy leads to a SVR rate similar to 
that of HCV-infected patients without MCS, and strongly suggested this combination as the first-line 
treatment for MCS patients. However, few patients occasionally show the persistence of cryoglobulins or 
symptoms even after the clearance of HCV RNA [56,57]. Furthermore, antiviral treatment is sometimes 
associated with major immune-mediated adverse events, such as peripheral sensorymotor neuropathy, 
thyroiditis, rheumatoid-like polyarthritis, and other vasculitic manifestations [8,17,58–63]. Because of its 
immunomodulatory properties, IFN may precipitate or exacerbate some pre-existing and often subclinical 
disorders. Unfortunately, there are no parameters for predicting these complications [8], and so antiviral 
therapy should be very carefully administered to patients with mixed cryoglobulinemiarelated peripheral 
neuropathy or active skin ulcers. Moreover, some patients may have major contraindications to IFN and/or 
RBV, such as advanced age, uncompensated cirrhosis, major uncontrolled depressive illness, significant 
coronary heart disease, untreated thyroid disease [51], which makes antiviral treatment inadvisable. Finally, 
the slow and uncertain response to antiviral therapy means that particularly severe and rapidly progressive 
MCS complications (including nephrotic or acute nephritic syndrome, extensive cutaneous ulcers, 
widespread vasculitis, and hyperviscosity syndrome) require prompter and more aggressive treatment; in 
such settings, antiviral therapy may be used after or concomitantly with more rapid, immunosuppressive 
regimens [8,16,64–66]. In clinical practise, the treatment of MCS should therefore be tailored to the 
individual patient on the basis of the progression and severity of its clinical manifestations [8,64,65]. RCTs 
with adequately sized populations and an appropriate follow-up are needed to clarify whether higher 
virological or clinical response rates can be obtained using different antiviral schedules, such as longer 
treatment duration in virological non-responders showing a clinical and laboratory improvement (up to 48 
weeks in the case of HCV genotypes 2 or 3, and 72 weeks in the case of HCV genotypes 1 or 4). On the 
basis of their answers to the questionnaire, almost all of the conference participants use Peg-IFN+ RBV in 
HCV-related MCS, although infectious disease specialists, gastroenterologists and hepatologists are more 
likely to use antiviral therapy than rheumatologists. Nevertheless, all of the experts agreed to extend the 
current standard of care for chronic HCV infection to MCS. Given the risks associated with progressive 
MCS, many of the participants also believe that MCS patients older than age limits established by the 
international guidelines can receive IFN-based treatment in the absence of other major contraindications. 
 
Statements  
• HCV RNA suppression is associated with an improvement or the disappearance of the clinical and 
laboratory manifestations of HCVrelated mixed cryoglobulinemia syndrome (MCS). The achievement of a 
sustained virological response (SVR) leads to a complete recovery from all signs and symptoms of disease in 
the majority of patients (3b C).  
• In patients with HCV infection, the presence of MCS does not substantially affect the rate of SVRs to 
combined pegylated interferon and ribavirin therapy (4 C). 
 • An attempt at viral eradication should be considered a first-line therapeutic option in patients with mild–
moderate HCV-related MCS in the absence of any major contraindication (4 C). 
• The current guidelines for the treatment of chronic hepatitis C should also be followed in the case of 
patients with HCV-related MCS (1b A). 
 • An extended duration of treatment (up to 48 weeks for HCV genotypes 2 or 3 and 72 weeks for HCV 
genotypes 1 or 4) may be considered in the case of virological non-responders who show clinical and 
laboratory improvements in MCS (5 D). 
 • The possible onset or worsening of some vasculitic manifestations (e.g. peripheral neuropathy, skin ulcers, 
etc.) should be carefully evaluated before starting treatment (5 D). 
 
Biological therapy 
Rituximab (RTX) and infliximab are the only two biological agents that have been tested in MCS so far. 
RTX has led to encouraging results in open studies and single case reports [67–93], whereas the initial 
results obtained using infliximab were contrasting and did not support its further use in MCS [94–96]. RTX 
is a monoclonal antibody against the CD20 antigen, which is selectively expressed on B cells. CD20-positive 
cells are expanded and activated in MCS, may harbour and present viral antigens, and play a crucial 
pathogenetic role in cryoglobulin production. The rationale underlying RTX treatment is to intervene 
downstream of the triggering disease mechanism more selectively than when the conventional 
immunosuppressive treatments are used [97]. It has been reported that RTX can improve or cure various 
clinical manifestations of MCS, including fatigue, skin manifestations (purpura and skin ulcers), arthralgias 
and arthritis, glomerulonephritis (GN) (in about 90% of cases), peripheral neuropathy (in about 75% of 
cases) and hyper-viscosity syndrome [67–93]. It has also been reported that it can also be effective in some 
life-threatening cases of gastrointestinal vasculitis [74,77]. GN responds to RTX within 1–6 months, more 
frequently within the first three months. Skin ulcers usually improve within three months, but complete 
healing requires a longer time [67,68,70]. Both sensitive and motor neuropathy improve within 1– 5 months, 
with a stable or improved electromyography picture [67,68,70–72,89]. At the time of the final review of our 
statements (October 2010), there were more than 150 published cases of MCS treated with RTX, most of 
which came from uncontrolled studies or single case reports. A recent multicentre RCT involving MCS 
patients who had failed or were not eligible for antiviral therapy compared RTX monotherapy (at the dose 
recommended in rheumatoid arthritis, i.e., 1 g every two weeks for a total of two infusions, with or without 
low-dose steroids) with the best conventional immunosuppressive treatment (corticosteroids, 
cyclophosphamide, azathioprine or plasma exchange, as chosen by the clinician) and the standard dose of 
RTX (375 mg/m2 in four weekly infusions) used in most published MCS cases. The preliminary results of 
the trial supported the superiority of RTX [98]. 
B cell depletion has occurred in the vast majority of MCS patients receiving RTX. It has also been reported 
that RTX decreases serum cryoglobulin and rheumatoid factor levels (although their disappearance is less 
frequent), and increases C4 levels. The activity of RTX is also supported by the restoration of some MCS-
related immune abnormalities [99], and the disappearance of bone marrow B cell clonal expansion 
[100,101]. The duration of the response to RTX is difficult to define because most of the studies lack long-
term follow-up data. However, while bearing in mind this limitation, it is worth noting that short-term 
relapses (within 3–4 months of RTX discontinuation) have been observed in a minority of patients, and long-
term responses (more than one year) have been the most frequent outcome. In some cases, more intense 
induction regimens or maintenance regimens have been attempted [69,71,73,74] Retreatment with RTX after 
a disease relapse has proved to be effective in most cases [67,70,71,74,78,79]. Maintenance RTX therapy has 
rarely been described in patients with MCS, but may be considered in those with severe nephritis or 
abdominal vasculitis [71,73,74]. Interestingly, RTX has a steroid-sparing effect in patients with MCS [67], 
some of whom (including cases with active nephritis) could be treated without steroids ab initio or with only 
short glucocorticosteroids courses [71,98]. Some authors suggest that naïve patients with serious clinical 
manifestations may receive RTX before antiviral therapy, which can be introduced later after the efficacy 
and safety of RTX have been assessed [97]. This advice is based on the observation of continuing MCS-
related symptoms in patients with persistently negative serum HCV RNA findings [57,102], which suggests 
that an autoimmune process can become independent of viral triggering and play a predominant role in the 
pathogenesis of the disease. Short-term reactions to RTX infusions do not seem to be any more frequent in 
MCS than in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or Sjogren's syndrome (SS). 
Serum sickness was never observed in most studies and appeared to be rarely reported (about 1% in pooling 
data), even with high RTX doses [80,98]. A French Group, however, reported a higher incidence of serum 
sickness (about 10%), though stating that RTX is overall well tolerated in MCS [103]. Therefore, patients 
should be carefully monitored, in particular when high cryocrit levels are present. Pre-medication with 100 
mg of methylprednisolone, anti-histamine drugs and paracetamol may reduce the risk of such reactions 
[104]. In patients with a history of heart failure or arrhythmia, consideration can be given to the 
administration of half a dose per day on two consecutive days and/ or to prolonging the administration of 
each infusion. RTX can increase HCV viral load, generally without significant liver impairment or serum 
albumin decrease [67,68,70,75]. At the time of submission of this paper, there were no data supporting a 
substantial risk of liver toxicity directly caused by RTX or HCV reactivation, although there is a lack of 
long-term follow-up data. Moreover, RTX has been given to MCS patients with liver cirrhosis and led to an 
improvement in MCS symptoms and liver function despite a transient increase in serum HCV RNA [86,93]. 
RTX may induce the severe reactivation of hepatitis B virus (HBV) infection and so, regardless of the 
presence of HBV DNA, should only be used in HBsAg-positive patients when strictly needed, and in 
combination with antiviral therapy. The same policy should be adopted in the case of potential occult HBV 
carriers (HBsAgnegative/anti-HBc-positive patients) [105]. Severe infections (lethal disseminated 
cryptococcosis and severe bacterial pneumonia) have been reported after RTX administration in two severely 
immunocompromised renal transplant recipients with type III cyoglobulin-related graft dysfunction [73,106]. 
On the contrary, no life-threatening infections have been reported in patients with typical HCV-relatedMCS. 
Progressivemultifocal leukoencefalopathy has been never reported in MCS after rituximab therapy. 
However, it must be remembered that the published reports have rarely provided longterm follow-up data. 
The conference participants concluded that special care should be given to the prevention and management 
of infections, particularly in patients previously treated with immunosuppressants or steroids, or those with 
low serum immunoglobulin levels. De novo hypo-gammaglobulinemia [76], panniculitis [67], neutropenia 
[67,71,75,101] and retinal vascular occlusion [67,68] have been rarely reported as side effects of RTX 
treatment for MCS. The administration of aspirin has been proposed in the case of patients at cardiovascular 
risk [67] or with GN [69]. Direct experience of the use of RTX for patients with MCS was reported by about 
70% of the conference participants. It has been hypothesised that the combination of antiviral and RTX 
therapy has a synergistic effect. Retrospective data and case reports have been published by French and 
Italian Authors [65,66,75,97]. Two very recent studies have compared combined therapy with antiviral 
treatment alone. A prospective, non-randomised cohort study of 93 patients found that combined therapy 
reduced the time to clinical remission (5.4± 4 versus 8.4± 4.7 months; P= 0.004), improved renal response 
rates (but not those of other organic manifestations), and led to higher rates of cryoglobulin clearance and 
clonal VH1-69+ B cell suppression than Peg-IFN+ RBV alone [107]. The authors concluded that the 
combined therapy is well tolerated and more effective than antiviral therapy alone. Similar results were 
achieved by the second study, which involved 37 patients [108]. However, none of these studies was 
designed to define the best first-line treatment in MCS and the advantages of combined therapy versus RTX 
monotherapy have never been investigated up to now in randomised trials. Some of the experts participating 
in the conference prefer the sequential treatment option (starting with RTX or antiviral therapy depending on 
the condition of the patient), and others favoured combination therapy ab initio. Nevertheless, all agreed that 
further investigations are required. 
 
Statements 
• Rituximab (RTX) is the only biological therapy that has proved to be beneficial in MCS, and should be 
considered when treating patients with severe clinical manifestations such as glomerulonephritis, skin ulcers 
or peripheral neuropathy (3 C).  
• In the same clinical situations, RTX should be preferred over other more conventional treatments such as 
glucocorticoids, immunosuppressants or apheresis (3 C).  
• In the same clinical situations, RTX may significantly reduce glucocorticoids administration (3 C).  
• The monitoring of RTX infusion reactions should follow the guidelines used in the other clinical situations 
in which the drug is used (5 C).  
• Patients receiving RTX should be carefully monitored for infectious complications, especially those with 
severe immunodepression (5 C).  
• HCV viral load and liver function should be carefully monitored in patients receiving RTX, and antiviral 
prophylaxis should be given to HBV carriers (5 C) statements.  
• Rituximab may be used in combination with antivirals in some cases of MCS (4 B). 
 
Glucocorticoids 
Glucocorticoids (GCs) are widely used to treat systemic vasculitis and, in the critical manifestation of MCS, 
have been prescribed at high doses (1–10 mg/kg) or as pulse therapy. Data from small case series support the 
effectiveness of high-dose pulse therapy in controlling disease flares [109–112]. The answers to our 
questionnaire indicated that high-dose pulse therapy is used by 94.7% of GISC centres, in the majority of 
cases for one single cycle and to treat a critical condition (renal, neurological or hyperviscosity syndromes). 
The long-term administration of low–medium GC doses (0.1– 0.5 mg/kg/day) is widely used in clinical 
practise, but the results of small controlled studies are conflicting [111–114]. Moreover, no studies have 
evaluated the effectiveness of long-term GC administration, although it is well known that the side effects of 
long-lasting steroid therapy can be very serious and irreversible. All of the GISC centres reported the use of 
low (0.1–0.5 mg/kg/day) or intermediate GC doses (0.5–2 mg/kg/day) to control vasculitis symptoms or pain 
in MCS patients: only occasionally and for short courses in 32%, and with treatment limited to a few weeks 
in a further 18%, but 36% have prescribed chronic treatments for more than one year. GCs are frequently 
used in combination with other drugs [109– 116], and a RCT comparing INF with combined IFN and steroid 
treatment found that the combination led to better results [111]. The consensus panel concluded that high-
dose GC pulse therapy is useful during MCS flares but, although there is considerable clinical experience of 
the use of low steroid doses, there are few data from controlled studies and therapeutic efficacy is 
controversial. Moreover, the side effects of long-lasting steroid therapy can be serious and irreversible, and 
careful patient monitoring is recommended to prevent them. 
 
Statements 
• High-dose or pulsed glucocorticoid (GC) therapy plays a substantial role in the management of critical 
patients with renal or neurological complications or serious vasculitic manifestations (4 C).  
• The use of low–intermediate GC doses (0.1–0.5 mg/kg/day) has proved ineffective (1b A), but it has been 
reported that they improve the results of IFN therapy (1b A). 
 • In the opinion of some experts, short courses (weeks) of low– intermediate GC doses might be considered 
to control vasculitic flares in patients who do not respond or who are refractory to other treatments (5 D). 
 • Chronic treatment with low GC doses should be avoided whenever possible and in any case carefully 
monitored. Alternative therapies (colchicine, a low-antigen-content diet) should be considered for the 
maintenance treatment of MCS (5 D). 
 
Apheresis  
Many different apheretic procedures have been used to treat various clinical situations associated with MCS 
but, in the absence of controlled trials and large cohort studies, the available data comes only from case 
reports [109,117–132]. Most of these date back to before the association of HCV and MCS was recognised, 
and apheretic methods used were significantly different. A number of observations support the role of 
apheresis in improving acute renal disease [118–120] and in treating neuritis [115,118] and ulcers [109,132]. 
Furthermore, it remains the first-choice treatment for cryoglobulinemic hyperviscosity syndrome despite the 
lack of RCT data, which are obviously difficult to obtain in this rare and dramatic condition. The use of 
combined apheresis and immunosuppressants is supported by some clinical reports [124–129], but the 
majority of conference participants suggested great caution in using these drugs, which should be avoided in 
the case of HBV-infected patients. There is some evidence that apheresis synchronised with the intravenous 
administration of high-dose immunoglobulins can be used to treat ulcers and MC-related peripheral 
neuropathy, but this may also have a considerable immunosuppressive effect [132]. Apheresis is used in 84% 
of GISC centres, the majority of them (87%) using it in combination with cytotoxic drugs; 53% of the 
centres accept treatments lasting for more than three months. Almost all of the centres reserve its use to the 
treatment of critical complications (renal or neurological impairment, or hyper-viscosity syndrome). Plasma 
exchange and double filtration are considered the best apheretic approaches [119,132], with many experts 
preferring plasma exchange in the case of life-threatening complications. There was no agreement among the 
experts concerning treatment intensity, duration or frequency. 
 
Statements  
• Apheresis (usually combined with other treatments) can be used in the case of severe, life-threatening 
cryoglobulinemic manifestations (4 C), and is the treatment of choice for hyper-viscosity syndrome (5 B).  
• Apheresis can be used to treat severe cryoglobulinemic manifestations when other therapies have failed or 
cannot be used (4 C).  
• Apheresis should be used very cautiously in patients with severe HCV liver disease (5 D), and the 
evolution of HCV or HBV infection should be carefully monitored after apheresis, particular when it has 
been combined with immunosuppressants (5 D). 
 
Cyclophosphamide  
Cyclophosphamide (CTX) is the cytotoxic drug that is most frequently used in MCS patients [121–129] but, 
as it is usually used in combination with apheresis or other drugs, it is often impossible to distinguish its 
specific effects. Moreover, most of the available data was collected before it was discovered that HCV is a 
major determinant of MCS and the risk of using CTX in HCV-infected patients is poorly defined. The 
rationale underlying the use of CTX to treat MCS seems to be that of obtaining temporary 
immunosuppression after acute apheretic treatment, but there are no data from large cohort studies or RCTs 
to support this. Our systematic search of the literature revealed only small case series [121–129] in which 
CTX has been mainly considered in the case of membrano-proliferative GN or severe polyneuropathy. The 
use of an intravenous CTX bolus is believed to be safer than oral administration as it reduces the cumulative 
dose [133]. Almost all of the GISC centres use CTX in combination with apheresis. HCV infection and liver 
function should be carefully monitored after the administration of CTX. The use of other 
immunosuppressants such as cyclosporine, azathioprine, and methotrexate to treat MCS was only anecdotal 
and could not be evaluated because of the lack of data. 
 
Statements  
• Despite some observations of improvements in renal function and purpura after cyclophosphamide (CTX) 
treatment, the use of CTX alone to treat MCS is not recommended. However, its combined use with 
apheresis can be considered in the case of serious MCS-related conditions, when other therapeutic 
approaches fail or are contraindicated (4 C).  
• CTX increases plasma HCV RNA levels (4 C) and the effects of CTX on liver function should be strictly 
monitored. 
 
Colchicine  
The rationale underlying the use of colchicine to treat MCS is based on the drug's activity in reducing Ig 
secretion [134,135]. A controlled, retrospective study of 17 patients treated with colchicine 1 mg/day for 6–
48 months showed that it had favourable effects on purpura, weakness, leg ulcers and MCS-related 
laboratory abnormalities. Mild to substantial gastrointestinal side effects may occur during the first 
days/weeks of therapy, and prolonged treatment can cause haematological abnormalities [134]. Colchicine is 
prescribed for symptomatic patients in 56% of GISC centres, 44% of which currently prescribe treatments 
lasting 2–3 years, stopping only when side effects appear or the patients enter stable remission. In the 
experts' opinion, colchicine seems to be safe and effective in controlling the symptoms of patients with mild 
MCS and, in such cases, can also be considered as a means of sparing steroid therapy when other treatments 
can not be administered. 
 
Statements  
• Purpura and pain can be improved by administering colchicine 1 mg/day for at least six months (4 C).  
• Long-term treatment maymaintain the effect and reduce glucocorticoid consumption (3b B). 
 
Low-antigen-content diet 
A low-antigen-content (LAC) diet can improve phagocyte activity and modify the composition of immune 
complexes. MCS patients who strictly follow such a diet experience a significant reduction in symptoms 
within 4–8 weeks [136,137]. A chronic LAC diet has a steroid sparing effect, reduces purpura and pain, is 
not expensive, and does not cause adverse effects; [138] however, some patients are not completely 
compliant or are unable to change their eating habits [116]. A LAC diet is currently used in 74% of GISC 
centres, 57% of which limit its use to symptomatic patients, 78% prescribe it for as long as possible (without 
any pre-defined limit), and 43% continue its prescription during MCS flares. 
 
Statements 
 • A low-antigen-content (LAC) diet improves MCS symptoms and laboratory abnormalities when strictly 
followed for 4–8 weeks (1b A).  
• A LAC diet can be considered as supportive treatment in all symptomatic MC patients (3b B). 
 
Analgesic and non-steroidal anti-inflammatory drugs  
Pain is one of the major symptoms of MCS, and often severely limits the patients' quality of life. 
Interventions aimed at controlling pain are frequently necessary, even when patients are undergoing a LAC 
diet or receiving antiviral therapy or colchicine. No published data are available concerning the use of 
analgesics or non-steroidal antiinflammatory drugs (NSAIDs) in patients with MCS. Among the potentially 
useful drugs controlling pain, the participating centres currently use gabapentin or pregabalin (87% of cases), 
acetaminophen (62%), opioids (31%), NSAIDs (31%), amitriptyline (25%), and benzodiazepines (12%), 
with the treatment for each patient being tailored on the basis of the physician's approach. The experts 
participating in the conference agreed to suggest acetaminophen as the first-choice analgesic. Combined 
analgesic treatments seem to be necessary in patients with severe pain associated with peripheral neuropathy. 
 
Statements  
• Interventions aimed at controlling any pain in MCS patients should be attempted even during the 
administration of ‘etiological’ treatments (5 C). 
 • In the absence of controlled studies, the management of pain in MCS patients should be individually 
tailored and based on the drugs that have proved to be effective in controlling pain due to other vasculitides 
and neuropathies (5 C.)  
 
The consensus recommendations are summarised in Table 1. 
 
Discussion  
The complexity of the etiopathogenesis of MCS and its polymorphic clinical manifestations make its 
treatment particularly challenging. Our Consensus Conference specifically focused on current strategies for 
treating MSC ‘as a whole’, leaving discussion of the management of its particular manifestations, such as 
skin ulcers, peripheral neuropathy, and GN to future projects. The relatively rare HCV-negative MCS and 
the monoclonal cryoglobulinemias (type I cryoglobulinemias in the immunochemical classification of Brouet 
et al.) [139] were also excluded as they presumably have a different pathogenesis from that of HCV-related 
MCS. The main limitation of the conference (but also the most important reason for holding it) was the 
scarcity of data from controlled trials of MCS treatment. However, the available data concerning the 
pathogenesis of the syndrome could be used as a reference to make some treatment suggestions when there 
were few or no clinical data. It was widely agreed that, regardless of the severity of MCS, an attempt to 
eradicate HCV should be made whenever possible because suppressing viral replication may limit or (in the 
most favourable cases) arrest the immunopathogenic process triggered by HCV [37,45–47,52–54]. Although 
the current guidelines for the treatment of chronic hepatitis C do not contraindicate antiviral treatment in 
patients with normal ALT and/or serum cryoglobulin levels, the percentage of MCS patients receiving 
antiviral treatment remains relatively low, regardless of the virus genotype, and depending on the 
specialisation of the caring centre. The lack of studies assessing the long-term results and side effects of 
antiviral treatment for MSC, or the best therapeutic schedule, may reduce the chances of its use, particularly 
in patients with mild–moderate liver disease. In clinical practise, the treatment of HCV-related MCS should 
be tailored to each individual patient on the basis of the progression and severity of the clinical 
manifestations. RCTs with an adequate statistical power and appropriate follow-up are required to clarify 
whether better response rates can be obtained by extending treatment duration in virological non-responders 
who show clinical and laboratory improvements after a standard course of Peg-IFN+RBV. Given the 
complete absence of data concerning the use of HCV polymerase or protease inhibitors in patients with 
MCS, no recommendations could be included in this paper. It is conceivable that trials of these drugs in 
MCS patients will be proposed in the near future. RTX treatment is proposed for patients with severe MCS, 
i.e. with active GN, skin ulcers, or worsening/refractory peripheral neuropathy [67–93]. A number of 
important papers on the use of this drug have been very recently published [66,88–93,108], but the clinical 
criteria for its use in MCS patients, as well as its optimal positioning in relation to antiviral therapy, need to 
be better defined. Preliminary data from the first longterm, multicentre, RCT comparing RTX monotherapy 
with conventional immunosuppressive treatment encouraged the use of RTX in patients not responding to or 
ineligible for antiviral therapy [98]. In our experts' opinion, high-dose glucocorticoid therapy can be 
administered together with RTX, but should be tapered and discontinued as soon as possible. The steroid-
sparing effect of RTX has been highlighted [98] and is a very important question that deserves further 
investigation. There is a rationale for combining RTX and antiviral therapy, but the advantages must be 
thoroughly investigated. Many other questions concerning the use of RTX in MCS patients remain open, 
including its long-term effects on liver function and immune response, response duration, re-treatment, and 
possible maintenance strategies, particularly in the case of severe, life-threatening manifestations. There was 
general agreement concerning the use of high-dose and pulsed GC therapy during MCS flares, when the 
severity of the clinical picture requires emergency intervention. On the contrary, the benefit of the chronic 
administration of low–medium doses was one of the most debated issues: the effectiveness of this treatment 
is questioned, and there is some evidence from controlled studies against its use. Moreover, the age of many 
patients, the frequent presence of co-morbidities, concomitant chronic HCV infection, and the risk of other 
infections are all significant caveats. However, as shown by the responses to the questionnaire, this 
therapeutic approach has been and is still widely used in GISC centres, particularly in the case of patients 
with mild–moderate MCS, and when IFN or RTX therapy are considered too hazardous. Nevertheless, the 
majority of the participating experts thought that the long-term administration of low–medium GC doses 
should be discouraged for its side effects. Colchicine may be an alternative for patients who have failed on, 
or could not be treated with antivirals or RTX. However, although it is quite widely use in GISC centres, 
most of the available data are anecdotal and little is known about the long-term side effects. Apheresis (with 
or without CTX) should be restricted to lifethreatening situations in which the other therapeutic approaches 
have failed or could not be used. A LAC diet is safe and inexpensive, and can be considered in all cases of 
MCS. Its only limitation is patient compliance, which may be insufficient. Finally, the conference strongly 
recommended the need to manage pain, which often greatly affects the quality of life of MCS patients. 
Unfortunately, this aspect has not yet been considered in any controlled trial. In conclusion, recent findings 
concerning the pathogenesis of MCS and the current availability of new drugs have significantly increased 
the possibility of treating MCS, and there is a possibility that other new drugs might improve treatment 
further in the near future. However, there is still a lack of RCT, and so physicians must still tailor individual 
treatments and make choices that are not always based on solid data. In the meantime, we hope that the 
recommendations made in this paper will help to support medical decision making. 
 
Take-home messages  
• Mixed cryoglobulins (MCs) are immune complexes that can precipitate at temperatures below 37 °C 
associated with acute and chronic infections, lymphoproliferative disorders, and autoimmune diseases.  
• The treatment is still largely empirical, but the rational therapeutic approach should have three main 
objectives - to eradicate HCV; to limit or suppress B lymphocyte proliferation; and to contain and 
symptomatically treat the vasculitis and reduce the damage caused by circulating immune complexes. 
• The GISC board organised the conference that is focused on what is known about the drugs used to treat 
MCS, and formulated the statements and the recommendations by combining the best available evidence 
from the literature with the experts' opinion.  
• In clinical practise, the treatment of HCV-related MCS should be tailored to each individual patient on the 
basis of the progression and severity of the clinical manifestations. 
 • All of the conference participants use pegylated interferon + ribavirin in HCV-related MCS, although 
infectious disease specialists, gastroenterologists and hepatologists are more likely to use antiviral therapy 
than rheumatologists. Nevertheless, all of the experts agreed to extend the current standard of care for 
chronic HCV infection to MCS. 
 • Rituximab treatment is proposed for patients with severe MCS, i.e. with active glomerulonephritis, skin 
ulcers, or worsening/ refractory peripheral neuropathy. 
• There is a rationale for combining rituximab and antiviral therapy, but the advantages must be thoroughly 
investigated.  
• Long-term administration of low–medium corticosteroid doses should be discouraged for its side effects.  
• Colchicine may be an alternative for patients who have failed on, or could not be treated with antivirals or 
rituximab. 
 • Apheresis (with or without cyclophosphamide) should be restricted to life-threatening situations in which 
the other therapeutic approaches have failed or could not be used.  
• A low-antigen-content diet is safe and inexpensive, and can be considered in all cases of MCS.  
• To manage pain, which often greatly affects the quality of life of MCS patients, is strongly recommended. 
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